Cizzle Biotechnology AZD 1656 deal means near term revenue streams (Interview)

Cizzle Biotechnology Holdings plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk Interviews to discuss an agreement with Conduit Pharmaceuticals and St George Street Capital to acquire a 5% economic interest in the commercialisation of the AZD 1656 asset.

Allan tells us more about the deal and how it fits with Cizzle’s previous agreement on AZD 1656, the history of the asset and what its looking to treat, who the partners Conduit Pharmaceuticals and St George Street Capital are and how this agreement will work from a financial point of view.

Cizzle Biotechnology is a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer.

You might also enjoy reading  Cizzle Biotechnology expands in the USA with new collaboration agreements

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Cizzle Biotechnology AZD 1656 deal means near term revenue streams (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions